Supplementary Table 1.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **PORTEC-1** | |  | **PORTEC-2** | |  |
|  | **Included** | **Excluded** |  | **Included** | **Excluded** |  |
|  | **n=477** | **n=237** | ***P-value*** | **n=384** | **n=43** | ***P-value*** |
| **Age, years** |  |  |  |  |  |  |
| Mean (range) | 66 (41-90) | 66 (43-88) | 0.387 | 70 (52-89) | 70 (46-85) | 0.471 |
| ˂ 60 | 131 (27.5) | 69 (29.1) |  | 14 (3.6) | 2 (4.7) | 0.585 |
| 60-70 | 179 (37.5) | 92 (38.8) | 0.731 | 190 (49.5) | 18 (41.9) |
| ˃ 70 | 167 (35.0) | 76 (32.1) |  | 180 (46.9) | 23 (53.4) |
| **Grade** |  |  |  |  |  |  |
| 1-2 | 400 (83.9) | 201 (84.8) | 0.743 | 345 (89.8) | 29 (67.4) | 0.000 0.212\*\* |
| 3 | 77 (16.1) | 36 (15.2) | 39 (10.2) | 13 (30.2) |
| **Myometrial** **invasion** |  |  |  |  |  |  |
| <50% | 198 (41.5) | 96 (40.5) | 0.798 | 61 (15.9) | 10 (23.3) | 0.379 |
| >50% | 279 (58.5) | 141 (59.5) | 323 (84.1) | 33 (76.7) |
| **LVSI**\* |  |  |  |  |  |  |
| Absent/Focal | 452 (95.6) | 125 (95.4) | 0.945 | 356 (94.9) | 29 (96.7) | 0.701 |
| Substantial | 21 (4.4) | 6 (4.6) | 19 (5.1) | 1 (3.3) |
| **Risk** **group** |  |  |  |  |  |  |
| Low | 216 (45.3) | 106 (44.7) |  | 36 (9.3) | 2 (4.7) | 0.000 0.339\*\* |
| High-intermediate | 234 (49.1) | 112 (47.3) | 0.477 | 327 (85.2) | 28 (65.1) |
| High | 27 (5.7) | 19 (8.0) |  | 21 (5.5) | 13 (30.2) |
| **Treatment** |  |  |  |  |  |  |
| NAT | 246 (51.6) | 123 (51.9) |  | 2 (0.5) | 1 (2.3) | 0.727 |
| EBRT | 231 (48.4) | 114 (48.1) | 0.934 | 190 (49.5) | 19 (44.2) |
| VBT | 0 | 0 |  | 192 (50.0) | 23 (53.5) |

LVSI - lymphovascular space invasion, NAT - No additional treatment, EBRT - External beam radiotherapy, VBT – Vaginal brachytherapy  
\* Degree of LVSI unknown for 13 included cases, and 119 excluded cases. \*\* Endometrioid EC only.